| A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID‐19) pandemic: an international collaborative group HO Al‐Shamsi, W Alhazzani, A Alhuraiji, EA Coomes, RF Chemaly, ... The oncologist 25 (6), e936-e945, 2020 | 817 | 2020 |
| Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with … M Moore, HW Hirte, L Siu, A Oza, SJ Hotte, O Petrenciuc, F Cihon, ... Annals of oncology 16 (10), 1688-1694, 2005 | 367 | 2005 |
| Current management of castrate-resistant prostate cancer SJ Hotte, F Saad Current oncology 17 (Suppl 2), S72, 2010 | 316 | 2010 |
| Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study SJ Hotte, EW Winquist, E Lamont, M MacKenzie, E Vokes, EX Chen, ... Journal of Clinical Oncology 23 (3), 585-590, 2005 | 309 | 2005 |
| Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline E Basch, DA Loblaw, TK Oliver, M Carducci, RC Chen, JN Frame, ... Journal of Clinical Oncology 32 (30), 3436-3448, 2014 | 308 | 2014 |
| Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America WM Stadler, RA Figlin, DF McDermott, JP Dutcher, JJ Knox, WH Miller Jr, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 300 | 2010 |
| Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non–adenoid cystic carcinoma … M Agulnik, EWE Cohen, RB Cohen, EX Chen, EE Vokes, SJ Hotte, ... Journal of Clinical Oncology 25 (25), 3978-3984, 2007 | 296 | 2007 |
| Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer KN Chi, SJ Hotte, EY Yu, D Tu, BJ Eigl, I Tannock, F Saad, S North, ... Journal of clinical oncology 28 (27), 4247-4254, 2010 | 291 | 2010 |
| A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies SJ Hotte, HW Hirte, EX Chen, LL Siu, LH Le, A Corey, A Iacobucci, ... Clinical Cancer Research 14 (11), 3450-3455, 2008 | 247 | 2008 |
| Plasma osteopontin: associations with survival and metastasis to bone in men with hormone‐refractory prostate carcinoma SJ Hotte, EW Winquist, L Stitt, SM Wilson, AF Chambers Cancer: Interdisciplinary International Journal of the American Cancer …, 2002 | 240 | 2002 |
| Guidelines for the management of castrate-resistant prostate cancer F Saad, SJ Hotte Canadian Urological Association Journal 4 (6), 380, 2010 | 199 | 2010 |
| Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND. 161) JJ Knox, SJ Hotte, C Kollmannsberger, E Winquist, B Fisher, ... Investigational new drugs 25, 471-477, 2007 | 185 | 2007 |
| Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled … R Mesía, M Henke, A Fortin, H Minn, ACY Ancona, A Cmelak, ... The Lancet Oncology 16 (2), 208-220, 2015 | 182 | 2015 |
| A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly … NG Chau, SJ Hotte, EX Chen, SF Chin, S Turner, L Wang, LL Siu Annals of oncology 23 (6), 1562-1570, 2012 | 160 | 2012 |
| Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate … F Saad, S Hotte, S North, B Eigl, K Chi, P Czaykowski, L Wood, M Pollak, ... Clinical Cancer Research 17 (17), 5765-5773, 2011 | 143 | 2011 |
| A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer KN Chi, LL Siu, H Hirte, SJ Hotte, J Knox, C Kollmansberger, M Gleave, ... Clinical cancer research 14 (3), 833-839, 2008 | 139 | 2008 |
| A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer KN Chi, SL Ellard, SJ Hotte, P Czaykowski, M Moore, JD Ruether, ... Annals of Oncology 19 (4), 746-751, 2008 | 138 | 2008 |
| An optimized clinical regimen for the oncolytic virus PV701 SJ Hotte, RM Lorence, HW Hirte, SR Polawski, MK Bamat, JD O'Neil, ... Clinical Cancer Research 13 (3), 977-985, 2007 | 137 | 2007 |
| Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. RM Lorence, AL Pecora, PP Major, SJ Hotte, SA Laurie, MS Roberts, ... Current opinion in molecular therapeutics 5 (6), 618-624, 2003 | 136 | 2003 |
| The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC) F Saad, KN Chi, A Finelli, SJ Hotte, J Izawa, A Kapoor, W Kassouf, ... Canadian Urological Association Journal 9 (3-4), 90, 2015 | 133 | 2015 |
